Emeryville, Calif. – September 25, 2026 -- Slingshot Biosciences has appointed Dr. Nimisha Srivastava as Chief Executive Officer, effective September 23, 2026, elevating the company's former Chief Operating Officer to its top leadership post.
Srivastava succeeds Glenn Bilawsky as CEO of the flow cytometry controls maker
Glenn Bilawsky is transitioning out of the CEO role at Slingshot Biosciences, a company specializing in precision-engineered cell mimics used as reference materials in flow cytometry. The Board of Directors credited Bilawsky's leadership contributions during his tenure.
Board chairman cites Srivastava's operational track record in leadership shift
Nicolas Barthelemy, Chairman of the Board of Slingshot Biosciences, said Srivastava's deep familiarity with the company's technology, customer base, and internal teams positions her to lead the next phase of growth. The Board stated it has full confidence in her leadership going forward.
New CEO brings synthetic biology manufacturing background from Twist Bioscience
Prior to joining Slingshot, Srivastava was a member of the founding engineering team at Twist Bioscience, where she led scale-up of laboratory processes, automated workflows, and high-throughput synthetic DNA and RNA production. That experience in scaling disruptive technologies and building high-throughput manufacturing is expected to inform her priorities at Slingshot.
Company to prioritize commercial growth and new product development under new leadership
As CEO, Srivastava will focus on accelerating commercial growth, advancing new product development, strengthening customer relationships, and executing against Slingshot's strategic priorities. Srivastava said the leadership transition would not alter the company's core focus: building the business, bringing innovative products to market, and growing its customer base.
Slingshot continues push to replace traditional biological reference materials
Slingshot Biosciences develops precision-engineered cell mimics designed to replace variable, perishable biological reference materials used in flow cytometry. The company's portfolio spans applications in cell therapy, drug development, diagnostics, and life sciences research, and the leadership transition is not expected to change the company's existing strategic direction.